Paradigm Shift in the In Vivo CAR-T Market

Eli Lilly (LLY) has reached a final agreement to acquire Kelonia Therapeutics, a Boston-based company specializing in in vivo gene delivery systems, for a total of $7 billion. This acquisition marks Eli Lilly's second major foray into the in vivo chimeric antigen receptor T-cell (CAR-T) space this year, following its $2.4 billion acquisition of Orna Therapeutics, a company focused on circular RNA (circRNA) technology. Unlike the conventional ex vivo CAR-T approach, which involves genetically modifying T cells outside the patient's body and then re-infusing them, in vivo CAR-T technology directly targets and modifies immune cells within the patient's body. This innovative platform is poised to overcome the limitations of existing CAR-T therapies, such as complex, customized manufacturing processes, weeks-long waiting times, and adverse effects associated with pre-conditioning lymphodepletion chemotherapy.

The Value of KLN-1010, a Phase 1 Pipeline Targeting BCMA

The key asset in this acquisition is KLN-1010, an in vivo CAR-T therapy candidate for multiple myeloma. This candidate is an off-the-shelf, single-dose intravenous gene therapy designed to target the B-cell maturation antigen (BCMA) on the surface of cancer cells and is currently in Phase 1 clinical trials. Kelonia's proprietary iGPS® (in vivo gene placement system) platform utilizes engineered lentiviral vector particles to selectively target T cells within the patient's body, endowing them with the ability to fight cancer. Preliminary clinical data, presented at the 2025 American Society of Hematology (ASH) and the 2026 American Society of Clinical Oncology (ASCO) meetings, demonstrated excellent drug delivery and a superior safety profile compared to existing ex vivo therapies, capturing the attention of the scientific community.

Competitive Landscape in the Multiple Myeloma Market

The global multiple myeloma market is a large and growing market, estimated at $25.88 billion to $31 billion in 2026, with an expected annual growth rate of 6-8%. By the mid-2030s, it is projected to exceed $40 billion. Currently, this market is dominated by existing ex vivo BCMA CAR-T therapies, such as Carvykti from Johnson & Johnson (JNJ) and Legend Biotech, and Abecma from Bristol Myers Squibb (BMS). However, these therapies have been criticized for their high production costs and long manufacturing times, which significantly limit patient access. By leveraging Kelonia's in vivo technology to enter the multiple myeloma market with an off-the-shelf product, Eli Lilly has the potential to capture a significant share of the market from existing competitors.

Eli Lilly's Gene Medicine Strategy and Outlook

With the acquisition of Kelonia, Eli Lilly has not only expanded its oncology portfolio but also solidified its position as a global leader in the field of gene medicine. The total transaction value of $7 billion includes an upfront payment of $3.25 billion, with the remaining $3.75 billion to be paid in clinical, regulatory, and commercial milestone payments. This is an unprecedented investment in a single platform technology in the biotech industry, reflecting Eli Lilly's confidence in the commercial success of in vivo CAR-T therapy. Ultimately, the combination of Orna's lipid nanoparticle (LNP) circRNA technology and Kelonia's lentiviral vector technology is expected to create a unique synergy in the development of next-generation cancer and autoimmune disease therapies.